Search

Your search keyword '"Kapoor, Prashant"' showing total 2,452 results

Search Constraints

Start Over You searched for: Author "Kapoor, Prashant" Remove constraint Author: "Kapoor, Prashant"
2,452 results on '"Kapoor, Prashant"'

Search Results

1. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma: MULTIPLE MYELOMA, GAMMOPATHIES

2. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome: MULTIPLE MYELOMA, GAMMOPATHIES

3. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

5. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms

6. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

7. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

9. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

10. Prognostic impact of patient-reported symptoms in multiple myeloma

11. Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes

13. Retreatment of multiple myeloma with previously refractory drugs

14. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies

15. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

16. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

18. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

19. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia

20. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

22. Muscle and fat composition in patients with newly diagnosed multiple myeloma

23. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

24. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

26. Utility of flow cytometry screening before MRD testing in multiple myeloma

27. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

29. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

31. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

34. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

35. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

36. Outcomes after biochemical or clinical progression in patients with multiple myeloma

37. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

38. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

39. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.

40. Autologous and Allogeneic Stem‐Cell Transplantation for Transformed Waldenström Macroglobulinemia.

41. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

42. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

43. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

44. Kidney Transplant Outcomes of Patients With Multiple Myeloma

46. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

47. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)–Associated Lesions: A Case Series

49. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

50. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

Catalog

Books, media, physical & digital resources